Drug-drug interaction mediated by inhibition and induction of P-glycoprotein, Adv. Drug Delivery Rev, vol.55, pp.53-81, 2003. ,
Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site, Biochemistry, vol.44, pp.643-655, 2005. ,
Communication between multiple drug binding sites on P-glycoprotein, Mol. Pharmacol, vol.58, pp.624-632, 2000. ,
New and Original pKa Prediction Method Using Grid Molecular Interaction Fields, J. Chem. Inf. Model, vol.47, pp.2172-2181, 2007. ,
Prediction of drug-ABC-transporter interaction-Recent advances and future challenges, Adv. Drug Delivery Rev, vol.86, pp.17-26, 2015. ,
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions, J. Pharmacol. Exp. Ther, vol.316, pp.336-348, 2006. ,
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature, BMC medicine, vol.14, p.10, 2016. ,
Protein Contacts and Ligand Binding in the Inward-Facing Model of Human P-Glycoprotein, ChemMedChem, vol.8, pp.748-762, 2013. ,
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein, Naunyn-Schmiedeberg's Arch. Pharmacol, vol.364, pp.551-557, 2001. ,
Rational use of in vitro P-glycoprotein assays in drug discovery, J. Pharmacol. Exp. Ther, vol.299, pp.620-628, 2001. ,
In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates, Drug Metab. Dispos, vol.34, pp.786-792, 2006. ,
Drug-drug interactions, 2008. ,
Why drugs fail-a study on side effects in new chemical entities, Curr. Pharm, 2005. ,
, , vol.11, pp.3545-3559
Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities, Eur. J. Biochem, vol.250, pp.130-137, 1997. ,
Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance, Anti-Cancer Drugs, vol.23, pp.865-873, 2012. ,
,
The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox), Drug discovery today, vol.13, pp.379-393, 2008. ,
Dealing with the complex drug-drug interactions: towards mechanistic models, Biopharm. Drug Dispos, vol.36, pp.71-92, 2015. ,
Inhibition of P-glycoprotein by newer antidepressants, J. Pharmacol. Exp. Ther, vol.305, pp.197-204, 2003. ,
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter, Invest. New Drugs, vol.32, pp.618-625, 2014. ,
Predicting drug-drug interactions: an FDA perspective, The AAPS journal, vol.11, pp.300-306, 2009. ,
Substrate-and species-dependent inhibition of p-glycoprotein-mediated transport: Implications for predicting in vivo drug interactions, J. Pharm. Sci, vol.100, pp.3055-3061, 2011. ,